Recurrent Liver Carcinoma Clinical Trial
The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study
will document for the first time the safety and the short and long term efficacy of the
combined therapy using IRE and NK cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;
|Source||Fuda Cancer Hospital, Guangzhou|
|Phase||Phase 1/Phase 2|
|Start date||December 1, 2016|
|Completion date||July 1, 2019|